Lab-on-a-chip and Microarrays (Biochip) Market 2021 Segments Analysis and Key Company Profiles | Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories Inc., GE Healthcare, Roche Holding AG, Fluidigm Corporation, Thermo Fisher Scientific, etc.

Biochips are increasingly being used in the field of biomedical and biotechnological research. With the advancement of technology, there has been a rise in the adoption of biochips in proteomics, such as in microarrays. The advantages of protein biochips include the low sample consumption and its inclination towards miniaturization. This characteristic of microarrays is important for proteome-wide analysis. Proteomics is being widely adopted for biomarker and drug discoveries. Moreover, there is a rise in the demand for personalized medicine that is contributing to the growth of the market. However, other factors, such as the increasing use of biochips in cancer treatment and diagnostics, demand for personalized medicine, and rapid technological advances in biochip technology are driving the lab-on-a-chip and microarrays (biochip) market.

The lab on a chip and microarrays (biochip) market is projected to register a CAGR of 14% during the forecast period.

The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Lab-on-a-chip and Microarrays (Biochip) Market on the basis of stating current situation of the industry in 2021.

This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market.

Request a Sample Copy Report:

https://www.reportconsultant.com/request_sample.php?id=90999

The following Companies are covered

Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories Inc., GE Healthcare, Roche Holding AG, Fluidigm Corporation, Thermo Fisher Scientific, etc.

Recent Developments

In April 2021, PathogenDx, Inc. announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its patented COVID-19 multiplexed viral diagnostic assay, DetectX-Rv. DetectX-Rv is a RT-PCR and DNA microarray hybridization test intended for the qualitative detection of nucleic acids from SARS-CoV-2 swabs.

In December 2020, Agilent Technologies Inc. announced today that it has recieved clearance from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the GenetiSure Dx Postnatal Assay, a microarray-based assay for diagnostic use. This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital anomalies, and unexplained dysmorphic features.

In June 2020, Singapore based Sengenics, the Functional Proteomics Company, has announced the launch of ImmuSAFE COVID+, a multi-antigen, multi-domain, fully quantitative serology test. The ImmuSAFE is a lab-based biochip test that utilises Sengenics’ patented KREX protein folding technology.

Overview

With the outbreak of COVID–19, the market is expected to have a net positive impact on the lab-on-a-chip and microarray market. The global pandemic has increased the focus on the development of less time-consuming diagnostic kits along with the increased use of lab-on-a-chip and microarray techniques in pharmaceutical R&D, which is likely to have a positive effect on the market.

Recently, one of the Singapore-based molecular diagnostics manufacturers, Veredus Laboratories in February 2020 has announced the commercial availability of their portable lab-on-chip diagnostic tool for the detection and differentiation 2019-nCoV, SARS-CoV, and MERS-CoV. This diagnostic test (VereCoV Detection Kit) combines both PCR and microarray technology, giving high specificity, sensitivity, and 2-hour turnaround time to result. Therefore, the healthcare facilities are looking for more accurate and less time-consuming diagnostic tests. Thus, most of the market players are focusing on the development of new and technologically advanced diagnostic tests. The lab-on-a-chip and microarray technology is expected to play an important role in it.

The major factors that are found driving the overall market are the increasing demand for point of care testing, increasing incidences of chronic diseases, and increasing application of proteomics and genomics in cancer research. 

The advancements have led to the development of new technologies and assays capable of easy and early detection of pathogenicity and the enhancement of the drug discovery and development pipelines. Hence, microfluidics can delay or prevent many chronic diseases through early diagnosis. Therefore, the rise in chronic diseases is fueling the growth of the lab-on-chip market, as it can offer a high-throughput screening of these diseases.

The Main objectives of this report are:

To analyze global Lab-on-a-chip and Microarrays (Biochip) status, future forecast, growth opportunity, key market and key players.
• To present the Lab-on-a-chip and Microarrays (Biochip) development in United States, Europe and China.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by product type, market and key regions.

Get Discount of this Report:

https://www.reportconsultant.com/ask_for_discount.php?id=90999

The research includes historic data from 2015 to 2021 and forecasts until 2028 which makes the report’s an invaluable resource for industry executives, Marketing, Sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Key Market Trends

Lab-on-a-chip Segment is Expected to Witness a Healthy Growth Over the Forecasted Period

The lab-on-a-chip segment is expected to have positive market growth due to the increasing global population and rising technological advancements. There is also a rise in the adoption of personalized medicine, and easy accessibility of lab-on-chip technology that will boost the demand for the same across the globe.

With the increasing COVID-19, there is an increasing number of researches that has boosted the lab on chip demand. For instance, Powerhouse researchers at the University of Alberta have joined forces to develop a handheld LOC device for rapidly detecting COVID-19 antibodies. Also, a low-cost imaging platform utilizing the lab-on-a-chip technology created by the University of California by Irvine scientists may be available for rapid coronavirus diagnostic and antibody testing.

The lab-on-a-chip concept targets miniaturizing laboratory procedures to allow automation and parallelization through microfluidic chips, which are capable of handling minute sample volumes. These devices save a lot of time, and reagents, as samples, are analyzed where they are generated. 

There are also various applications of LOC that are growing rapidly. Lab-on-a-chip devices equipped with electrodes for particle or cell detection, particle packing, sorting, electrophoresis, PCR, etc., are commercially available. Lab-on-a-chip devices are also excellent tools for cell research, such as cell sorting and cell growth, and fields, such as artificial disease models and toxicity studies. Some of the major applications of LOC include diagnosis of infectious disease, handheld diagnostics, and detection of analytes.

Furthermore, the market has witnessed frequent developments in lab-on-a-chip (LOC) platforms-based immunoassays. Such advanced LOC platforms are expanding and include microfluidic chips, paper, lateral flow, electrochemistry, and new biosensor concepts. The rapid increase in demand for point-of-care diagnosis has also been the most prominent driver, which is expected to propel the segment during the forecast period.

Buy Now Link:

https://www.reportconsultant.com/enquiry_before_buying.php?id=90999

Furthermore, this study will help to solve the following issues:

Cyclical Dynamics-Report foresee dynamics of industries by using core analytical and unconventional market research approaches.
• Identifying key cannibalizes– Strong substitute of a product or service is the most prominent threat. Report includes key cannibalizes of a market, by procuring market research. This helps in aligning new product development/launch strategies in advance.
• Spotting emerging trends- Report helps to spot upcoming hot market trends. Report also track possible impact and disruptions which a market would witness by a particular emerging trend.
• Interrelated opportunities- This report will allow to make decisions based on data, thereby increasing the chances that the strategies will perform better.

Note- At Report Consultant, our main forte is to custom make research reports as per your requirements. Do share your niche requirements, if any.

Contact us:
Riaana Singh
(Report Consultant)
sales@reportconsultant.com | www.reportconsultant.com

About Us:

Report Consultant – A worldwide pacesetter in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly by taking calculative risks leading to lucrative business in the ever-changing market. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies.

Our research reports will give you the most realistic and incomparable experience of revolutionary market solutions. We have effectively steered business all over the world through our market research reports with our predictive nature and are exceptionally positioned to lead digital transformations. Thus, we craft greater value for clients by presenting progressive opportunities in the global futuristic market.

This release was published on openPR.